Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers
Matthias Pauthner(Scripps Research Institute), Dennis R. Burton(Scripps Research Institute), David T. Evans(University of Wisconsin–Madison), Raiza Bastidas(Scripps Research Institute), Jérémie Prévost(Public Health Agency of Canada), Ian A. Wilson(Raigmore Hospital), Lars Hangartner(Scripps Research Institute), George M. Shaw(International AIDS Vaccine Initiative), Jeong Hyun Lee(Scripps Research Institute), Shane Crotty(La Jolla Institute for Immunology), Samantha Reiss(La Jolla Institute for Immunology), Ben Murrell(Karolinska Institutet), Richard T. Wyatt(Scripps Research Institute), Peter Abbink(Beth Israel Deaconess Medical Center), Talar Tokatlian(Integrated BioTherapeutics (United States)), Andrés Finzi(Centre Hospitalier de l’Université de Montréal), Daniel W. Kulp(The Wistar Institute), Matteo Bianchi(Scripps Research Institute), Dan H. Barouch(Beth Israel Deaconess Medical Center), Bartek Nogal(Unknown), William R. Schief(Scripps Research Institute), Andrew B. Ward(Scripps Research Institute), Benjamin von Bredow(Oakland University), Rogier W. Sanders(Scripps Research Institute), Darrell J. Irvine(Howard Hughes Medical Institute), Joseph P. Nkolola(Beth Israel Deaconess Medical Center), Hui Li(Guangdong Province Women and Children Hospital), Salvatore T. Butera(Scripps Research Institute), Rebecca Nedellec(Scripps Research Institute), Christopher A. Cottrell(Scripps Research Institute), Colin Havenar‐Daughton(VIR Biotechnology (United States))
Cited by 179
Related Papers
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k